Advertisement

Optimizing Immunosuppression

  • Alexander C. Wiseman
  • James E. Cooper
Chapter

Abstract

While short-term outcomes in kidney transplantation have improved significantly over the last decades, questions remain regarding long-term improvements in graft survival. Whereas long-term graft survival was reported to improve significantly from the mid-1980s to the mid-1990s, a more recent analysis has shown an equivalent relative risk of graft failure for those transplanted in 1995 through 2000 despite a reduction in acute rejection rates of nearly 50% during that time. Thus, attention has shifted to medication regimens that not only prevent early acute rejection but also take into consideration drug side-effect profiles, ease of use, and effect on long-term graft function.

Keywords

Acute Rejection Graft Survival Acute Rejection Episode Chronic Allograft Nephropathy Steroid Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors wish to thank the Scientific Registry of Transplant Recipients for supplying data used to generate Fig. 10.1 within this chapter. The data and analyses reported in the 2007 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients have been supplied by UNOS and Arbor Research under contract with HHS. The authors alone are responsible for reporting and interpreting these data.

References

  1. 1.
    Hariharan S et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342(9):605–612.CrossRefPubMedGoogle Scholar
  2. 2.
    Meier-Kriesche HU et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4(3):378–383.CrossRefPubMedGoogle Scholar
  3. 3.
    Nankivell BJ et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349(24):2326–2333.CrossRefPubMedGoogle Scholar
  4. 4.
    Meier-Kriesche HU et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 2006;6(5 Pt 2):1111–1131.CrossRefPubMedGoogle Scholar
  5. 5.
    Ojo AO et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349(10):931–940.CrossRefPubMedGoogle Scholar
  6. 6.
    Veenstra DL et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999;33(5):829–839.CrossRefPubMedGoogle Scholar
  7. 7.
    Prasad GV et al. Renal transplant recipient attitudes toward steroid use and steroid withdrawal. Clin Transplant 2003;17(2):135–139.CrossRefPubMedGoogle Scholar
  8. 8.
    Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003;75(12):2048–2053.CrossRefPubMedGoogle Scholar
  9. 9.
    Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003;14(11):2980–2984.CrossRefPubMedGoogle Scholar
  10. 10.
    Vincenti F et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73(5):775–782.CrossRefPubMedGoogle Scholar
  11. 11.
    Schulak JA et al. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation 1990;49(2):327–332.CrossRefPubMedGoogle Scholar
  12. 12.
    Hricik DE et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993;4(6):1300–1305.PubMedGoogle Scholar
  13. 13.
    Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992;147(5):645–657.PubMedGoogle Scholar
  14. 14.
    Kasiske BL et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11(10):1910–1917.PubMedGoogle Scholar
  15. 15.
    Vanrenterghem Y et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000;70(9):1352–1359.CrossRefPubMedGoogle Scholar
  16. 16.
    Ahsan N et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil – a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999;68(12):1865–1874.CrossRefPubMedGoogle Scholar
  17. 17.
    Sola E et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002;34(5):1689–1690.CrossRefPubMedGoogle Scholar
  18. 18.
    Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002;34(5):1584–1586.CrossRefPubMedGoogle Scholar
  19. 19.
    Hricik DE et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2007;83(3):277–281.CrossRefPubMedGoogle Scholar
  20. 20.
    Pascual J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004;78(10):1548–1556.CrossRefPubMedGoogle Scholar
  21. 21.
    Almawi WY, Melemedjian OK, Rieder MJ. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant 1999;13(5):365–374.CrossRefPubMedGoogle Scholar
  22. 22.
    Freise CE et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg 2003;138(10): 1121–1125; discussion 1125–1126.CrossRefPubMedGoogle Scholar
  23. 23.
    Kaufman DB et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002;73(2):169–177.CrossRefPubMedGoogle Scholar
  24. 24.
    Khwaja K et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004;4(6):980–987.CrossRefPubMedGoogle Scholar
  25. 25.
    Vincenti F et al. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc 2001;33(1–2):1011–1012.CrossRefPubMedGoogle Scholar
  26. 26.
    Matas AJ et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005;5(10):2473–2478.CrossRefPubMedGoogle Scholar
  27. 27.
    Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term results. Am J Transplant 2005;5(10):2539–2548.CrossRefPubMedGoogle Scholar
  28. 28.
    Kumar MS et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006;81(6):832–839.CrossRefPubMedGoogle Scholar
  29. 29.
    Woodle ES et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248(4):564–577.PubMedGoogle Scholar
  30. 30.
    Vincenti F et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8(2):307–316.CrossRefPubMedGoogle Scholar
  31. 31.
    Abramowicz D et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002;74(12):1725–1734.CrossRefPubMedGoogle Scholar
  32. 32.
    Smak Gregoor PJ et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13(5):1365–1373.CrossRefPubMedGoogle Scholar
  33. 33.
    Ekberg H et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007;7(3):560–570.CrossRefPubMedGoogle Scholar
  34. 34.
    Abramowicz D et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005;16(7):2234–2240.CrossRefPubMedGoogle Scholar
  35. 35.
    Hazzan M et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006;82(5):657–662.CrossRefPubMedGoogle Scholar
  36. 36.
    Johnson RW et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72(5):777–786.CrossRefPubMedGoogle Scholar
  37. 37.
    Kreis H et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004;15(3):809–817.CrossRefPubMedGoogle Scholar
  38. 38.
    Oberbauer R et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005;18(1):22–28.CrossRefPubMedGoogle Scholar
  39. 39.
    Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003;75(8):1404–1408.CrossRefPubMedGoogle Scholar
  40. 40.
    Grinyo JM et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004;4(8):1308–1314.CrossRefPubMedGoogle Scholar
  41. 41.
    Stallone G et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003;75(7):998–1003.CrossRefPubMedGoogle Scholar
  42. 42.
    Dudley C et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” study. Transplantation 2005;79(4):466–475.CrossRefPubMedGoogle Scholar
  43. 43.
    Schena FP et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87(2):233–242.CrossRefPubMedGoogle Scholar
  44. 44.
    Mulay AV et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006;82(9):1153–1162.CrossRefPubMedGoogle Scholar
  45. 45.
    Vincenti F et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71(9):1282–1287.CrossRefPubMedGoogle Scholar
  46. 46.
    Asberg A et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006;82(1):62–68.CrossRefPubMedGoogle Scholar
  47. 47.
    Flechner SM et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007;83(7):883–892.CrossRefPubMedGoogle Scholar
  48. 48.
    Groth CG et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67(7):1036–1042.CrossRefPubMedGoogle Scholar
  49. 49.
    Kreis H et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69(7):1252–1260.CrossRefPubMedGoogle Scholar
  50. 50.
    Morales JM et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2(5):436–442.CrossRefPubMedGoogle Scholar
  51. 51.
    Flechner SM et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74(8):1070–1076.CrossRefPubMedGoogle Scholar
  52. 52.
    Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006;6(3):514–522.CrossRefPubMedGoogle Scholar
  53. 53.
    Srinivas TR et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007;7(3):586–594.CrossRefPubMedGoogle Scholar
  54. 54.
    Ekberg H et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562–2575.CrossRefPubMedGoogle Scholar
  55. 55.
    Vincenti F et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353(8):770–781.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag US 2010

Authors and Affiliations

  1. 1.Kidney and Pancreas Transplant Program, Department of NephrologyUniversity of ColoradoAuroraUSA
  2. 2.Department of NephrologyUniversity of ColoradoAuroraUSA

Personalised recommendations